Phase 1Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Sponsored by Kura Oncology, Inc.
About this study
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Enrolling at this location
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
I'm interestedThis study also enrolls at 21 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.